Peptides Studied for Men's Libido: Research Overview

Key Takeaways

• Compounds covered: PT-141 (bremelanotide), kisspeptin
• Goal area: Men's libido, sexual desire, and erectile function
• Evidence range: PT-141: FDA-approved for acquired, generalized HSDD in premenopausal women; earlier Phase II data in men from a male-ED program that was not pursued to Phase III. Kisspeptin: investigator-initiated RCT in men with HSDD (Dhillo 2023) and multiple fMRI mechanistic studies.
• Regulatory range: PT-141 (Vyleesi) is FDA-approved only for acquired, generalized HSDD in premenopausal women — the label explicitly excludes men and postmenopausal women. Kisspeptin is not FDA-approved for any indication.
• Key biomarkers for libido: Total testosterone, free testosterone, LH, FSH, SHBG, estradiol, prolactin, comprehensive metabolic panel
• Bottom line: PT-141 and kisspeptin act through distinct mechanisms — melanocortin CNS signaling and HPG axis stimulation respectively — and are not interchangeable. This article is educational; any consideration of either compound is a clinical decision between a patient and a licensed prescriber.

Understanding Male Libido: The Biology

Sexual desire in men is not a single biological event — it is the product of at least two intersecting systems: the hormonal axis that provides the biochemical substrate for desire, and the central nervous system circuitry that generates and processes sexual motivation at the level of the brain and spinal cord.

The hormonal pathway is anchored by the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin neurons project onto GnRH-secreting neurons in the hypothalamus, driving GnRH pulsatile release, pituitary LH and FSH secretion, and ultimately Leydig cell testosterone synthesis in the testes. Testosterone acts on androgen receptors throughout the brain — including in the limbic system and the medial preoptic area — to modulate the neurological substrate of sexual motivation. Xie and colleagues, in their 2022 Frontiers in Endocrinology review, established that kisspeptin governs reproductive function. George and colleagues' 2012 study reported that kisspeptin restores testosterone in hypogonadal men — establishing the hormonal route by which kisspeptin acts on libido.

The central nervous system pathway is governed largely by the melanocortin system. MC3R and MC4R — expressed in the hypothalamus, limbic system, and spinal cord — are central to generating and coordinating sexual arousal, independent of vascular or hormonal status. Martin and colleagues, in a 2004 European Urology paper, mapped MC3R and MC4R distribution in the CNS and spinal cord, supporting the model that PT-141's effects operate through brain and spinal cord circuits rather than peripheral vascular mechanisms. This distinction is the proposed explanation for the Phase II observation that PT-141 was associated with erectile response in some men whose vascular PDE5 inhibitor pathway was functioning normally but whose CNS arousal circuitry appeared impaired (Safarinejad 2008, Rosen 2004) [Phase II RCT].

Kisspeptin's role extends beyond the HPG axis. Comninos and colleagues' 2017 Journal of Clinical Investigation fMRI study reported that kisspeptin modulates sexual and emotional brain processing in men — a neuroimaging finding that the authors interpreted as evidence for kisspeptin acting as a neuromodulator of sexual brain processing in addition to its endocrine role [Phase II mechanistic RCT]. Comninos and Dhillo, in their 2018 Neuroendocrinology review, positioned kisspeptin as a neuromodulator of desire involving olfaction, audition, mood, and sexual arousal across multiple species — a broader role than its HPG axis function alone suggests. Understanding both systems is the biological framework for why these two compounds address overlapping but distinct aspects of male sexual health.

Peptides Studied for Male Libido: A Quick Comparison

The following peptides have published evidence relevant to male sexual function. They are listed by strength and directness of clinical evidence for sexual function endpoints in men.

• Compound: PT-141 (bremelanotide)
  Mechanism studied: MC3R and MC4R agonism in CNS and spinal cord; acts on brain and spinal arousal circuits independent of the vascular/PDE5 pathway
  Evidence: FDA-approved for acquired, generalized HSDD in premenopausal women (Phase III, women); earlier Phase II data in men from a male-ED program that was not pursued to Phase III
  FDA status: FDA-approved as Vyleesi only for acquired, generalized HSDD in premenopausal women; the label explicitly excludes men, postmenopausal women, and use to enhance sexual performance
  Route studied: Subcutaneous injection approximately 45 minutes before sexual activity (Vyleesi label)
• Compound: Kisspeptin
  Mechanism studied: HPG axis stimulation via KISS1R agonism (GnRH → LH → testosterone); limbic neuromodulation with documented effects on brain responses to sexual cues
  Evidence: Investigator-initiated randomized, double-blind, placebo-controlled trial in men with HSDD (Dhillo 2023); multiple fMRI mechanistic studies
  FDA status: Not FDA-approved for any indication. Kisspeptin is not on FDA's approved 503A bulks list as of April 2026, has no USP/NF monograph, and is not a component of any FDA-approved drug — meaning none of the three § 353a(b)(1)(A) bulk drug substance sourcing pathways is available for kisspeptin. There is no FDA-endorsed 503A compounding pathway for kisspeptin. Some state-licensed pharmacies may dispense kisspeptin under patient-specific prescription arguments, but this practice is outside the FDA-endorsed framework
  Route studied: Subcutaneous injection or intravenous (clinical trial setting)

Peptides Studied for Male Libido: Individual Profiles

PT-141 and kisspeptin target sexual function through fundamentally different mechanisms. Neither is interchangeable with the other. Selecting the more mechanistically appropriate compound — or evaluating whether both are relevant — requires laboratory and clinical evaluation of the underlying cause of reduced desire.

PT-141 (bremelanotide)

PT-141 is a synthetic melanocortin receptor agonist — a heptapeptide acting on MC3R and MC4R in the central nervous system and spinal cord. Unlike PDE5 inhibitors, which enhance vascular response to existing arousal, PT-141 acts at the level of the brain to generate and coordinate the sexual response. Pfaus and colleagues, in their 2022 CNS Spectrums review, characterized the central melanocortin pathway involved in PT-141's mechanism — including the hypothalamic and limbic circuits responsible for desire generation and arousal initiation. Shadiack and colleagues' 2007 review positioned the melanocortin class in sexual dysfunction, distinguishing MC3R and MC4R roles in erection versus desire. Van der Ploeg and colleagues, in a 2002 PNAS paper, identified MC4R as the erectogenic receptor in animal models — the molecular evidence supporting PT-141's targeted mechanism.

The clinical evidence for PT-141 in men consists of multiple Phase II RCTs conducted prior to the Vyleesi approval for women. Molinoff and colleagues introduced PT-141 in a 2003 Annals of the New York Academy of Sciences paper, establishing its CNS mechanism and therapeutic rationale. In Diamond and colleagues' 2004 double-blind placebo-controlled study published in the International Journal of Impotence Research, intranasal PT-141 was associated with erectile response at doses above 7 mg in healthy males and mild-to-moderate ED patients [Phase II RCT]. Rosen and colleagues, in a 2004 International Journal of Impotence Research study, reported on the pharmacokinetics and pharmacodynamics of subcutaneous PT-141, characterizing erectile response in the study population [Phase II RCT]. Safarinejad and Hosseini, in a 2008 Journal of Urology randomized double-blind placebo-controlled study, reported that PT-141 salvaged sildenafil failures in a cohort of men who had not responded to sildenafil [Phase II RCT]. Diamond and colleagues' 2005 Urology study of low-dose intranasal PT-141 co-administered with sildenafil reported an additive erectile response in the study population [Phase II RCT] — the investigators proposed that CNS and vascular pathways may be additive when both are relevant. These Phase II data were generated during PT-141's earlier development for male sexual dysfunction, which was not pursued to a Phase III registration trial in men due in part to cardiovascular safety findings; the current FDA-approved indication is for HSDD in premenopausal women, not male sexual dysfunction.

Ückert and colleagues' 2014 Expert Opinion on Investigational Drugs review synthesized the melanocortin literature, covering the evidence base that informed bremelanotide's eventual FDA approval pathway. Mayer and Lynch, in a 2020 Annals of Pharmacotherapy paper, summarized the FDA approval basis for bremelanotide — Phase III trial evidence for HSDD that does not extend to an approved men's indication. Simon and colleagues' 52-week open-label safety extension study in Obstetrics & Gynecology (2019) reported safety and tolerability over long-term use in women — the longest safety dataset available, though not specific to men. [FDA-approved Phase III RCT for women; Phase II RCT data in men from a discontinued male-ED program]

PT-141 is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women. Its use for male sexual dysfunction is not an approved indication; the Vyleesi label explicitly excludes men, postmenopausal women, and use to enhance sexual performance. The safety and efficacy for male sexual dysfunction have not been established through adequate and well-controlled FDA-level clinical trials, and the male development program was discontinued in part due to cardiovascular safety findings. PT-141 causes a transient blood pressure elevation approximately 12 minutes post-injection — clinically relevant particularly for men with cardiovascular disease. Any use in men is a case-by-case practice-of-medicine decision by the licensed prescriber, not a Superpower-offered product. The prescriber's evaluation would need to address the specific cardiovascular safety concerns that contributed to the male development program's discontinuation — including a transient post-injection blood-pressure elevation that was more concerning in the male ED population than in the subsequent Vyleesi approval pathway for premenopausal women at a different dose.

Kisspeptin

Kisspeptin's relevance to male libido spans two pathways — hormonal and neuromodulatory. On the hormonal side, kisspeptin stimulates GnRH release from the hypothalamus via KISS1R agonism, driving the HPG axis cascade that produces endogenous testosterone. Dhillo and colleagues' 2005 study reported that kisspeptin-54 increased LH, FSH, and testosterone in the study population of men. Khan and Chaudhry's 2021 Journal of the Pakistan Medical Association review characterized kisspeptin deficiency in functional hypogonadism, proposing kisspeptin as a physiologically relevant target when HPG axis suppression is the driver.

On the neuromodulatory side, kisspeptin acts directly on the limbic system and reward circuitry independent of testosterone. In Comninos and colleagues' 2017 Journal of Clinical Investigation fMRI study, kisspeptin modulates sexual brain processing, amplifying limbic activation in response to sexual visual cues [Phase II mechanistic RCT]. Their 2018 JCI Insight paper reported that kisspeptin alters default-mode connectivity in ways that correlated with reward-drive measures [Phase II mechanistic RCT]. Yang and colleagues' 2020 JCI Insight paper reported that kisspeptin enhances responses to sexual cues in men [Phase II mechanistic RCT].

The clinical evidence most directly relevant to men's HSDD is Mills and colleagues' 2023 randomized, double-blind, placebo-controlled mechanistic trial published in JAMA Network Open (Dhillo senior author). In that study, kisspeptin modulated sexual brain processing and was associated with changes in penile tumescence and behavioral measures of sexual desire in men with hypoactive sexual desire disorder [investigator-initiated RCT] — the most direct and most recent published clinical evidence for kisspeptin in men. A companion 2022 paper by Thurston and colleagues in JAMA Network Open studied kisspeptin in women with HSDD and reported comparable pro-desire effects in women [investigator-initiated RCT].

[Investigator-initiated RCT in men with HSDD; multiple fMRI mechanistic studies] Kisspeptin is not FDA-approved for any indication. Kisspeptin is not on FDA's approved 503A bulks list, has no USP/NF monograph, and is not a component of any FDA-approved drug — none of the three § 353a(b)(1)(A) bulk drug substance sourcing pathways is available. There is no FDA-endorsed 503A compounding pathway for kisspeptin. Some state-licensed pharmacies may dispense kisspeptin under patient-specific prescription arguments outside the FDA-endorsed framework. The Dhillo 2023 study is a mechanistic/proof-of-concept academic trial, not a formal Phase II/III registration trial under an FDA IND; the safety and efficacy of compounded kisspeptin for male HSDD have not been established through FDA-level pivotal trials.

Regulatory Status at a Glance

As of April 2026, the compounds discussed in this article carry the following regulatory statuses.

• PT-141 (bremelanotide / Vyleesi): FDA-approved only for acquired, generalized HSDD in premenopausal women. The label explicitly excludes men, postmenopausal women, and use to enhance sexual performance. Any use in men is off-label under the practice of medicine and has not been evaluated or endorsed by the FDA.
• Kisspeptin: Not FDA-approved for any indication. Kisspeptin is not on FDA's approved 503A bulks list, has no USP/NF monograph, and is not a component of any FDA-approved drug — no FDA-endorsed 503A compounding pathway exists. Some state-licensed pharmacies may dispense kisspeptin under patient-specific prescription arguments outside the FDA-endorsed framework. Any prescribing and compounding is a case-by-case clinical determination made by a licensed prescriber and pharmacy outside FDA's formally approved pathway.

Understanding the Mechanistic Differences: Research Context

The published research on PT-141 and kisspeptin in men addresses different biological pathways. Understanding these differences is useful context for a conversation with a licensed provider, but does not constitute patient-selection guidance — neither compound is FDA-approved for men's libido, and any clinical decision is a case-by-case practice-of-medicine determination by an individual licensed prescriber based on the specific patient's full clinical picture.

Mechanism context for PT-141 research: The published PT-141 studies in men focused on men with erectile dysfunction, including a subset who had not responded to PDE5 inhibitors. The mechanistic rationale was that CNS melanocortin activation could address a sexual-response deficit not addressable by peripheral vascular mechanisms.

Mechanism context for kisspeptin research: The published kisspeptin studies in men (Dhillo 2005, Comninos 2017/2018, Yang 2020, Mills/Dhillo 2023) focused on (a) HPG axis stimulation in men with HPG axis suppression, and (b) CNS-level sexual brain processing independent of testosterone.

Cardiovascular safety consideration for PT-141: PT-141 causes a transient blood pressure elevation approximately 12 minutes post-injection. The male development program was discontinued in part due to cardiovascular safety findings. This history is material to any conversation about PT-141 in men, even at the off-label practice-of-medicine level.

Evidence-level transparency: Both compounds have Phase II human data related to sexual function in men. Neither has completed Phase III pivotal trials for male sexual dysfunction. PT-141's Phase III evidence base is for HSDD in premenopausal women (the FDA-approved indication for Vyleesi). Kisspeptin's most recent evidence in men (Mills/Dhillo 2023) is an investigator-initiated mechanistic RCT, not a formal Phase III registration trial.

This is not clinical guidance. A licensed provider — ideally with experience in men's sexual health and endocrinology — would evaluate the full clinical picture including hormone panel, cardiovascular profile, and medical history before making any prescribing decision. Neither compound is an approved men's libido therapy.

Safety Considerations

Safety profiles for these two compounds reflect different mechanisms and different evidence depths. PT-141 has the most systematically characterized human safety profile in this category given FDA-level clinical trial oversight; kisspeptin has Phase II human safety data without Phase III scale.

PT-141 causes a transient blood pressure increase approximately 12 minutes post-injection. This is the most important safety signal for clinical use in men. It is not clinically significant for most healthy men but represents a meaningful risk in men with cardiovascular disease, uncontrolled hypertension, or concurrent nitrate use. Nausea is the most commonly reported side effect — occurring in approximately 40% of women in Phase III trials — followed by flushing, headache, and injection site reactions. PT-141 is administered on-demand approximately 45 minutes before sexual activity; it is not a daily medication, limiting cumulative exposure.

Kisspeptin interacts directly with HPG axis pulsatility. Effects on LH pulsatility and testosterone at therapeutic doses in men have not been characterized through large-scale Phase III safety monitoring. The 2023 Dhillo JAMA Network Open trial represents the most rigorous published safety data in men with HSDD, but the study was not powered for long-term safety assessment.

Contraindications that apply broadly to libido-focused peptide therapy in men include:

• Significant cardiovascular disease or uncontrolled hypertension — PT-141 causes transient blood pressure elevation; not appropriate without cardiovascular evaluation
• Concurrent nitrate use — PT-141 is contraindicated with nitrate medications; the mechanism of interaction is distinct from PDE5 inhibitors but clinically relevant
• Active hormone-sensitive malignancy — kisspeptin has been associated with elevations in testosterone via HPG stimulation in study populations; prostate cancer evaluation is part of pre-treatment assessment in men over 40
• Structural hypogonadism (primary hypogonadism with elevated LH/FSH) — kisspeptin targets upstream HPG signaling; primary hypogonadism does not respond to upstream stimulation
• Initiating either compound without a prescriber relationship and baseline lab evaluation — the cause of reduced libido determines which mechanism is appropriate, and this cannot be assessed without lab data

For compound-specific side effect profiles, consult the FDA-approved prescribing information for Vyleesi (bremelanotide) at dailymed.nlm.nih.gov.

What to Test Before Starting Peptides for Libido

Baseline hormonal testing identifies the most probable biological cause of reduced libido and determines which compound mechanism is most appropriate. Reduced desire can reflect hormonal deficiency (kisspeptin's primary target), CNS arousal pathway impairment (PT-141's primary target), or both — and this distinction requires laboratory data, not self-assessment.

• Total testosterone: The primary hormonal marker for libido evaluation in men. Testing total testosterone establishes whether deficiency is present and provides the baseline for monitoring response to kisspeptin.
• Free testosterone: The biologically active fraction. Free testosterone can be clinically low with borderline total testosterone when SHBG is elevated, explaining reduced desire despite apparently normal total T.
• LH (luteinizing hormone): The pituitary signal distinguishing HPG axis suppression (low LH with low testosterone, where kisspeptin is appropriate) from primary hypogonadism (elevated LH with low testosterone, where upstream stimulation would not work). Testing LH is the critical diagnostic step.
• FSH (follicle-stimulating hormone): Pairs with LH to complete the HPG axis evaluation. FSH is also relevant for men concerned about fertility implications of HPG axis therapies.
• SHBG (sex hormone-binding globulin): Elevated SHBG reduces free testosterone bioavailability and can explain reduced libido even when total testosterone appears normal.
• Estradiol: Aromatization of testosterone to estradiol affects libido. Both very low estradiol and elevated estradiol relative to testosterone can impair sexual function. Testing estradiol establishes the T:E2 ratio.
• Prolactin: Elevated prolactin suppresses GnRH release, reduces LH and FSH, and directly impairs sexual desire independent of its effect on testosterone. A prolactin baseline screens for hyperprolactinemia as a correctable cause of low libido that should be identified before any peptide therapy is initiated.
• Comprehensive metabolic panel: Liver and kidney function are relevant safety baselines before any injectable compound. Metabolic markers (glucose, liver enzymes) also provide context for whether insulin resistance or metabolic dysfunction is suppressing HPG axis function.

Total testosterone, free testosterone, LH, FSH, SHBG, estradiol, and prolactin together establish the complete hormonal picture that determines which mechanism is most relevant for reduced libido. In Superpower's libido and fertility biomarker guide, these markers are discussed in clinical context.

How These Peptides Are Accessed in Clinical Practice

Both PT-141 and kisspeptin are prescription compounds in the United States. Any prescribing decision is made by a licensed provider following a clinical evaluation that includes the hormone panel, cardiovascular profile, and health history.

PT-141 is FDA-approved as Vyleesi only for acquired, generalized HSDD in premenopausal women. The approved label explicitly excludes men. Any prescribing of PT-141 (or of a compounded bremelanotide) in men would be an off-label, case-by-case practice-of-medicine decision by an individual licensed prescriber, not a Superpower-offered product. Under FDCA § 353a(b)(1)(D), 503A compounding of a product that is "essentially a copy" of a commercially available FDA-approved drug (Vyleesi) requires a prescriber-documented determination that the compounded formulation meaningfully differs for the specific patient.

Kisspeptin is not FDA-approved for any indication and is not on FDA's approved 503A bulks list as of April 2026. No FDA-endorsed 503A compounding pathway exists for kisspeptin (no bulks-list inclusion, no USP/NF monograph, not a component of an FDA-approved drug). Any availability through state-licensed compounding pharmacies operates outside the FDA-endorsed framework and is a case-by-case clinical determination.

Self-administered peptides obtained online without a provider relationship bypass the clinical evaluation that determines whether a given mechanism is even relevant for the specific patient, the cardiovascular screening that identifies contraindications for PT-141, and the hormonal baseline that distinguishes which compound, if any, is mechanistically applicable.

Understanding Your Baseline

Reduced libido in men sits at the intersection of two biological systems — the hormonal axis and the central nervous system arousal circuitry — and these two systems can fail independently or together. Baseline biomarker data establishes which is contributing. A man with low LH, low testosterone, and normal PT-141 relevance needs a different clinical conversation than a man with normal testosterone and normal LH whose desire impairment reflects CNS-level changes. Without the lab data, these presentations are indistinguishable by symptoms alone.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the provider conversation leads toward kisspeptin for HPG axis support, PT-141 for CNS melanocortin pathway activation, a combination addressing both, or a different intervention entirely, the starting point is the same: objective data about where your biology currently stands.

IMPORTANT SAFETY INFORMATION

PT-141 (bremelanotide) is FDA-approved as Vyleesi only for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The approved label explicitly excludes men, postmenopausal women, and use to enhance sexual performance. The safety and efficacy for male sexual dysfunction have not been established through adequate and well-controlled clinical trials, and the male development program was discontinued in part due to cardiovascular safety findings.

Do not use PT-141 if you: have uncontrolled high blood pressure; have known cardiovascular disease requiring nitrate use; have a history of serious cardiovascular events. PT-141 causes a transient mean maximum increase in blood pressure of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking approximately 12 minutes post-injection (per Vyleesi prescribing information). Avoid use with antihypertensive agents or where blood pressure elevation would be clinically dangerous without prescriber evaluation.

Common side effects of PT-141 (from Vyleesi clinical trials in women): nausea (approximately 40%), flushing, headache, injection site reactions, hyperpigmentation with chronic use. Long-term safety data specific to men from controlled trials is limited.

Kisspeptin is not FDA-approved for any indication. Kisspeptin is not on FDA's approved 503A bulks list as of April 2026, has no USP/NF monograph, and is not a component of any FDA-approved drug — no FDA-endorsed 503A compounding pathway exists. Any compounded kisspeptin dispensed by state-licensed pharmacies operates outside the FDA-endorsed framework and is not the same as any FDA-approved product. The safety, efficacy, and optimal dosing of compounded kisspeptin for male hypoactive sexual desire disorder have not been established through FDA-level Phase III clinical trials. Factors a prescriber would evaluate before any kisspeptin use include active hormone-sensitive malignancy (kisspeptin has been associated with elevated testosterone via HPG stimulation in study populations) and primary (structural) hypogonadism (kisspeptin targets upstream HPG signaling, which will not function when structural damage is present).

All injectable peptides discussed in this article require a prescription from a licensed healthcare provider. No compound discussed in this article should be obtained or self-administered outside a licensed prescriber relationship. This article is educational content; any prescribing decision is a case-by-case practice-of-medicine determination made by an individual licensed provider.

Full FDA prescribing information for Vyleesi (bremelanotide) at dailymed.nlm.nih.gov.